Natural Killer Cell-Enriched Donor Lymphocyte Infusions from A 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 8, 2010, Pages 1107-1114

  Rizzieri, David A ^a   Storms, Robert ^a   Chen, Dong Feng ^a   Long, Gwynn ^a   Yang, Yiping ^a   Nikcevich, Daniel A ^b   Gasparetto, Cristina ^a   Horwitz, Mitchell ^a   Chute, John ^a   Sullivan, Keith ^a   Hennig, Therese ^a   Misra, Debashish ^a   Apple, Christine ^a   Baker, Megan ^a   Morris, Ashley ^a   Green, Patrick G ^a   Hasselblad, Vic ^a   Chao, Nelson J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Duluth Clinic   (United States)

Author keywords

NK cells; T cell depleted transplantation

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN;

ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; NATURAL KILLER CELL; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PHENOTYPE; T CELL DEPLETION; T LYMPHOCYTE;

ADULT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; STEM CELL TRANSPLANTATION; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 77954315403     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.02.018     Document Type: Article

References (38)

1. Rizzieri D.A., Long G., Vredenburgh J., et al. Successful allogeneic engraftment of mismatched unrelated cord blood following non-myeloablative conditioning. Blood 2001, 98:3486-3488.
2. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000, 343:750-758.
3. Rizzieri D.A., Koh L.P., Long G.D., et al. Clinical outcome and immune reconstitution following Alemtuzumab T cell depleted mismatched non-myeloablative allogoneic immunotherapy. J Clin Oncol 2007, 25:690-697.
4. Burroughs L.M., O'Donnell P.V., Sandmaier B.M., et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:1279-1287.
5. Falda M., Busca A., Baldi I., et al. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. Am J Hematol 2007, 82:863-866.
6. Keil F., Kalhs P., Haas O., et al. Relapse of Philadelphia chromosome positive acute lymphoblastic leukemia after marrow transplantation: sustained molecular remission after early and dose-escalating infusion of donor leukocytes. Br J Haematol 1997, 97:161-164.
7. Drobyski W., Keever C., Roth M., et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: effficacy and toxicity of a defined T cell dose. Blood 1993, 82:2310-2318.
8. Gurman G., Arslan O., Koc H., et al. Donor leukocyte infusion for relapsed ANLL after allogeneic BMT and the use of interferon alpha to induce graft versus leukemia effect. Bone Marrow Transplant 1996, 18:825-826.
9. Vago L., Perna S., Zanussi M., et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009, 361:478-488.
10. Ruggeri L., Cappani M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoetic transplants. Science 2002, 295:2097-2100.
11. Costello R.T., Fauriat C., Sivori S., et al. NK cells: innate immunity against hematological malignancies?. Trends Immunol 2004, 25:328-333.
12. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
13. http://ctep.cancer.gov/forms/ctcaev3to2.pdf.
14. FACT. Standards for Hematopoietic Progenitor Cell Collection, Processing, & Transplantation, 2nd ed. 2002.
15. Rizzieri D.A., Dev P., Long G.D., et al. Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors. Bone Marrow Transplant 2009, 43:327-333.
16. Mielcarek M., Storb R. Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. Leuk Lymphoma 2005, 46:1251-1260.
17. Morris E.C., Rebello P., Thomson K.J., et al. Pk of alemtuzumab used in vivo and in vitro in allogeneic transplantation. Blood 2003, 102:404-406.
18. Ruggeri L., Cappani M., Cassuci M., et al. Role of natural killer cells alloreactivity in HLA-mismatched hematopoetic stem cell transplantation. Blood 1999, 94:333-339.
19. Zoller M. Immunotherapy of cancer for the elderly patient: does allogeneic bone marrow transplantation after nonmyeloablative conditioning provide a new option?. Cancer Immunol Immunother 2004, 53:659-676.
20. Parham P., McQueen K.L. Alloreactive killer cells: hindrance and help for hematopoetic transplants. Nat Rev 2003, 3:108-122.
21. Schulze A., Schirutschke H., Oelschlägel U., et al. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation. Exp Hematol 2008, 36:378-389.
22. Vago L., Forno B., Sormani M., et al. Temporal, quantitative, and functional characteristics of single KIR + alloreactive natural killer cell recovery account for impaired GVL activity after haploidentical hematopoietic stem cell transplantation. Blood 2008, 112:3488-3499.
23. Motohashi S., Ishikawa A., Ishikawa E., et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2006, 12:6079-6086.
24. Ishikawa E., Tsuboi K., Saijo K., et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 2004, 24:1861-1871.
25. Shi J., Tricot G., Szmania S., et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008, 143:641-653.
26. Duwendag J, Huppert V, Alex R, et al. Optimized clinical scale selection of CD 56+CD3- natural killer cells for cellular immunotherapy. 20th International NK Cell Workshop, Noordwjkerhout, The Netherlands (Abstract), 2004.
27. Wolf I, Duwendag J, Arendt A, et al. Isolation of CD56+ natural killer cells using the CliniMACS MARRS Tubing Set, a newly developed Tubing Set including a cross-flow filtration module for removal of unbound agent. Annual Meeting of American Society of Hematology, San Diego, California, USA (Abstract), 2004.
28. Leemhuis T., Wells S., Scheffold C., et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005, 11:181-187.
29. Lopez R.D., Xu S., Guo B., et al. CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood 2000, 96:3827-3837.
30. Dodero A., Carniti C., Raganato A., et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 2009, 113:4771-4779.
31. Krebs P., Barnes M., Lampe K., et al. NK cell-mediated killing of target cells triggers robust antigen-specific T cell mediated and humoral responses. Blood 2009, 113:6593-6602.
32. Dunbar E.M., Buzzeo M.P., Levine J.B., Schold J.D., Meier-Kriesche H.U., Reddy V. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease. Haematologica 2008, 93:1852-1858.
33. Pende D., Marcenaro S., Falco M., et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and re-definition of inhibitory KIR specificity. Blood 2009, 113:3119-3129.
34. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
35. Cooper M., Fehniger T., Caligiuri M. The biology of human natural killer-cell subsets. Trends Immunol 2001, 22:633-640.
36. Caligiuri M. Human natural killer cells. Blood 2008, 112:461-469.
37. Prasad V., Chen D., Broadwater G., et al. Differential Impact of inhibitory and activating killer Ig-like receptors and HLA Ligand on outcomes of transplantation for myeloid and lymphoid malignancies. Blood 2008.
38. Cooley S., Trachtenberg E., Bergemann T.L., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009, 113:726-732.